Bio-Techne Corporation (TECH) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Minneapolis, MN, United States. Le PDG actuel est Kim Kelderman.
TECH a date d'introduction en bourse 1989-02-09, 3,100 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $9.18B.
Bio-Techne Corporation is a life sciences company that develops, manufactures, and sells reagents, instruments, and diagnostic services for research and clinical markets globally. Operating through two main segments—Protein Sciences and Diagnostics and Genomics—the company offers a comprehensive portfolio including biological reagents, antibodies, cytokines, proteomic analytical tools, and diagnostic assays for oncology, genetic screening, and molecular diagnostics. Its products serve cell and gene therapy, tissue analysis, and hematology applications under recognized brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, and Asuragen. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has established itself as a trusted supplier to academic institutions, pharmaceutical companies, clinical laboratories, and diagnostic centers worldwide.
